29 September 2017 - PHARMAC is interested in receiving proposals for dual and/or sole supply market share of permanent coronary drug-eluting stents used in District Health Board hospitals in New Zealand, for a three-year term.

In April 2014, PHARMAC invited suppliers to submit their registrations of interest to supply products in scope of the Interventional Cardiology category. From that process, PHARMAC has negotiated non-exclusive national contracts with 13 suppliers.

PHARMAC has been working to determine strategies going forward regarding managing future assessment, standardisation, prioritisation, and procurement of interventional cardiology devices that best meet patient care requirements. 

Read PHARMAC notification